Results 81 to 90 of about 21,018 (198)
Chronic graft‐versus‐host disease in long‐term survivors of childhood leukemia
HemaSphere, Volume 10, Issue 1, January 2026.Abstract Hematopoietic stem cell transplantation (HSCT) is a curative treatment for high‐risk childhood leukemia but may lead to chronic graft‐versus‐host disease (cGvHD), a severe long‐term complication. This study analyzed data from the LEA cohort, including 446 childhood leukemia survivors treated with allogeneic HSCT.
Paul Saultier +25 more
wiley +1 more source
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an [PDF]
, 2018 Katharina Arnheim
openalex +1 more source
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL) [PDF]
, 2023 H. Lee +18 more
openalex +1 more source
Hematological Oncology, Volume 44, Issue 1, January 2026.ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli +7 more
wiley +1 more source
Blood Neoplasia: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
June-Wha Rhee +6 more
doaj +1 more source
Descriptive Analysis of Dosing and Outcomes for Patients with Ibrutinib-Treated Relapsed or Refractory Chronic Lymphocytic Leukemia in a Canadian Centre [PDF]
, 2019 Kelsey Uminski +8 more
openalex +1 more source
Medicinal Research Reviews, Volume 46, Issue 1, Page 238-271, January 2026.ABSTRACT Solute carrier transporters (SLCs) are integral membrane proteins that play pivotal roles in maintaining cellular homeostasis by mediating the transport of a diverse range of substrates across cell membranes. With their involvement in fundamental physiological processes such as nutrient uptake, neurotransmitter signaling, and drug transport ...
Majlen A. Dilweg +3 more
wiley +1 more source
[Application of ibrutinib in primary central nervous system lymphoma].
, 2020 Diwen Pang, F L Chen, W Y Li
openalex +2 more sources
A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA [PDF]
, 2017 Craig S. Sauter +15 more
openalex +1 more source